UBS Group »

Xtl Biopharmaceuticals shares owned by UBS Group

Quarter-by-quarter ownership of Xtl Biopharmaceuticals (XTLB) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Xtl Biopharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Xtl Biopharmaceuticals held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xtl Biopharmaceuticals by UBS Group

Quarter filed Position value Share count Share price at filing
2026-06-30 $341 125 2.73

More positions owned by UBS Group

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Micron Technology (MU)
Eli Lilly & Co. (LLY)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Advanced Micro Devices (AMD)
Alphabet Cap Stk Cl C (GOOG)
Meta Platforms Cl A (META)
Ishares Tr Core Msci Eafe (IEFA)

View all positions for UBS Group

Top funds holding Xtl Biopharmaceuticals

Rhumbline Advisers
GAMMA Investing
UBS Group
Morgan Stanley

View all funds holding Xtl Biopharmaceuticals